Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia by Lim, Pharath et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Malaria Journal
Open Access Research
Pfmdr1 copy number and arteminisin derivatives combination 
therapy failure in falciparum malaria in Cambodia
Pharath Lim*1, Alisa P Alker2, Nimol Khim1, Naman K Shah2, 
Sandra Incardona1, Socheat Doung3, Poravuth Yi3, Denis Mey Bouth4, 
Christiane Bouchier5, Odile Mercereau Puijalon6, Steven R Meshnick2, 
Chansuda Wongsrichanalai7, Thierry Fandeur6, Jacques Le Bras8, 
Pascal Ringwald9 and Frédéric Ariey1
Address: 1Institut Pasteur in Cambodia, 5 Monivong Boulevard, P.O Box 983, Phnom Penh, Cambodia, 2Department of Epidemiology, UNC 
School of Public Health, Chapel Hill, NC, USA, 3National Center for Parasitology, Entomology and Malaria Control (CNM), Phnom Penh, 
Cambodia, 4World Health Organization, Phnom Penh, Cambodia, 5Pasteur Genopole Ile de France, Institut Pasteur, France, 6Institut Pasteur, 
Unité d'Immunologie Moléculaire des Parasites, CNRS URA 2581, France, 7Independent Scholar, 130 Sub Street, Bangkok 10500, Thailand, 
8Faculté des sciences pharmaceutiques et biologiques, EA209 Université Paris Descartes, France and 9Global Malaria Department, World Health 
Organization, Headquarters, Geneva, Switzerland
Email: Pharath Lim* - pharath@pasteur-kh.org; Alisa P Alker - alkera@gmail.com; Nimol Khim - knimol@pasteur-kh.org; 
Naman K Shah - topnaman@gmail.com; Sandra Incardona - sandra.incardona@yahoo.fr; Socheat Doung - socheatd@cnm.gov.kh; 
Poravuth Yi - yiporavuth@yahoo.com; Denis Mey Bouth - denism@cnm.gov.kh; Christiane Bouchier - bouchier@pasteur.fr; 
Odile Mercereau Puijalon - omp@pasteur.fr; Steven R Meshnick - meshnick@email.unc.edu; 
Chansuda Wongsrichanalai - dr.chansuda@gmail.com; Thierry Fandeur - tfandeur@pasteur.fr; Jacques Le Bras - jacques.lebras@gmail.com; 
Pascal Ringwald - ringwaldp@who.int; Frédéric Ariey - fariey@pasteur-kh.org
* Corresponding author    
Abstract
Background: The combination of artesunate and mefloquine was introduced as the national first-
line treatment for Plasmodium falciparum malaria in Cambodia in 2000. However, recent clinical
trials performed at the Thai-Cambodian border have pointed to the declining efficacy of both
artesunate-mefloquine and artemether-lumefantrine. Since pfmdr1  modulates susceptibility to
mefloquine and artemisinin derivatives, the aim of this study was to assess the link between pfmdr1
copy number, in vitro susceptibility to individual drugs and treatment failure to combination
therapy.
Methods: Blood samples were collected from P. falciparum-infected patients enrolled in two in
vivo efficacy studies in north-western Cambodia: 135 patients were treated with artemether-
lumefantrine (AL group) in Sampovloun in 2002 and 2003, and 140 patients with artesunate-
mefloquine (AM group) in Sampovloun and Veal Veng in 2003 and 2004. At enrollment, the in vitro
IC50 was tested and the strains were genotyped for pfmdr1 copy number by real-time PCR.
Results: The pfmdr1 copy number was analysed for 115 isolates in the AM group, and for 109
isolates in the AL group. Parasites with increased pfmdr1 copy number had significantly reduced in
vitro susceptibility to mefloquine, lumefantrine and artesunate. There was no association between
pfmdr1 polymorphisms and in vitro susceptibilities. In the patients treated with AM, the mean
pfmdr1copy number was lower in subjects with adequate clinical and parasitological response
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compared to those who experienced late treatment failure (n = 112, p < 0.001). This was not
observed in the patients treated with AL (n = 96, p = 0.364). The presence of three or more copies
of pfmdr1 were associated with recrudescence in artesunate-mefloquine treated patients (hazard
ratio (HR) = 7.80 [95%CI: 2.09–29.10], N = 115), p = 0.002) but not with recrudescence in
artemether-lumefantrine treated patients (HR = 1.03 [95%CI: 0.24–4.44], N = 109, p = 0.969).
Conclusion: This study shows that pfmdr1 copy number is a molecular marker of AM treatment
failure in falciparum malaria on the Thai-Cambodian border. However, while it is associated with
increased IC50 for lumefantrine, pfmdr1 copy number is not associated with AL treatment failure in
the area, suggesting involvement of other molecular mechanisms in AL treatment failures in
Cambodia.
Background
Since the report of chloroquine resistance along the Thai-
Cambodian border in the late 1950s [1], Southeast Asia
has been an important focus for the emergence and spread
of drug resistance in Plasmodium falciparum. In Cambodia,
chloroquine resistance prompted the change to sul-
phadoxine-pyrimethamine (SP) as first-line treatment in
the 1970s. Resistance to SP occurred and the first-line
treatment was then changed to mefloquine monotherapy
in 1993. However, by the mid-1990s, resistance to meflo-
quine exceeded 25% (RI-RIII) in western Cambodia [2].
After several clinical trials, the combination of artesunate
with mefloquine (AM) was introduced in 2000 in the
most multidrug-resistant areas in the west of the country
[3]. This regimen initially had a 28-day parasitological
cure rate of approximately 95%. After four years of moni-
toring the efficacy of AM for the treatment of uncompli-
cated falciparum malaria, there is now evidence that the in
vitro susceptibility of Cambodian strains to mefloquine is
decreasing [2,4]. There is a risk that, like resistance to chlo-
roquine and SP, mefloquine resistance will spread beyond
Southeast Asia.
Recent studies showed that increased copy number of
pfmdr1 was the best overall predictor of mefloquine treat-
ment failure [5-7]. Increased pfmdr1 copy number pre-
dicted failure even after chemotherapy with the highly
effective mefloquine and artesunate combination [5].
Monitoring pfmdr1 copy number may be an effective sur-
veillance tool for drug resistance in Southeast Asia [7].
Investigation of pfmdr1  polymorphisms and gene copy
number were performed using isolates from western Cam-
bodia, an area endemic for multidrug-resistant falciparum
malaria. The data was then compared to the clinical as
well as in vitro response outcome for two separate treat-
ment groups: AM (combination of artesunate and meflo-
quine) and AL (combination of artemether and
lumefantrine (Coartem®). The aim of this study was to
determine whether pfmdr1  polymorphism and/or
increased gene copy number was predictive of arylami-
noalcohol (mefloquine and lumefantrine) and endoper-




The National Malaria Control Programme of Cambodia
(CNM) conducted three therapeutic efficacy studies at
Sampovloun Referral Hospital, Battambang Province
(western Cambodia): 1. artemether-lumefantrine
between June and August 2002 (AL2002, N = 55), 2. arte-
mether-lumefantrine between October 2003 and March
2004 (AL2003, N = 80) [8] and 3. artesunate-mefloquine
between October 2003 and March 2004 (AM2003, N =
55) [9]. One therapeutic efficacy study of AM was con-
ducted at Veal Veng Referral Hospital, Pursat Province
(western Cambodia) between July and August 2004
(AM2004, N = 85) [9]. The studies followed the WHO
standard protocol for the assessment of the efficacy of
anti-malarial drugs [10]. Briefly, all patients over six years
of age and weight > 16 kg presenting with fever, defined as
axillary temperature ≥ 37.5°C or history of fever during 24
h prior to consultation, and a positive smear with Plasmo-
dium falciparum mono-infection, with parasite density of
1,000–150,000 parasites/μl, were included in the studies.
Informed consent was given by the patient or by a parent/
guardian for children. Enrolled patients had to stay in
hospital until blood smear became negative and had to
commit to completing the 28-day follow-up. Exclusion
criteria are: one or more of the general danger signs or any
sign of severe and complicated malaria, pregnancy, febrile
diseases other than malaria and severe malnutrition, and
known hypersensitivity or contraindication to the study
drugs. A total dose of 12 mg/kg artesunate and 25 mg/kg
mefloquine were given over 3 days (AM group). The daily
4 mg/kg of artesunate were divided into two equal doses,
one in the morning and one in the evening on day 0, and
4 mg/kg single dose on day 1 and 2 with a maximum
adult dose of 600 mg in total. The 25 mg/kg of meflo-
quine were also divided into two equal doses in the morn-
ing and in the evening on day 0. The maximum dose of
mefloquine was limited to 1,500 mg for adults as the side
effects are common beyond this dose [9]). In the arte-Malaria Journal 2009, 8:11 http://www.malariajournal.com/content/8/1/11
Page 3 of 9
(page number not for citation purposes)
mether-lumefantrine study group (AL group), subjects
were treated with 20 mg/kg artemether and 120 mg/kg
lumefantrine the first day at 0 and 8 hours and twice daily
(morning and late afternoon) on the following two days
(Coartem®, Novartis, Switzerland), i.e. 8–12 h apart (the
total dose of 24 tablets for an adult as recommended by
the manufacturer). In the AL2003 study, each dose of arte-
mether-lumefantrine was provided with 250 ml milk and
5 pieces of coconut biscuit [8]. Patients were checked by
malaria smear for the presence of parasites on study days
1, 2, 3, 7, 14, 21 and 28. If fever occurred at any time
between the scheduled study days, a malaria smear was
also done. People who did not present on their own were
actively sought for. The therapeutic response was classi-
fied as early treatment failure (ETF), late clinical failure
(LCF), late parasitological failure (LPF) and adequate clin-
ical and parasitological response (ACPR) according to
WHO protocols.
Site and blood sampling
Blood samples (5 ml) from patients were collected before
treatment in EDTA Vacutainers, and were transported to
the Institut Pasteur in Cambodia at 4°C within 48 hours
of collection for in vitro assays. An aliquot of each isolate
was frozen at -80°C for molecular analysis. If parasitae-
mia recurred, an additional blood sample was collected
onto 3 M Whatman filter paper and transported to the
laboratory at room temperature, then kept at -20°C until
DNA extraction.
Preparation of drugs and plates
Quinine hydrochloride was obtained from Sigma (Ger-
many). Mefloquine, chloroquine diphosphate, arte-
mether and artesunate were obtained from WHO/TDR
Drug Discovery Research (Geneva). Lumefantrine was
obtained from Novartis Pharma (Vietnam). Stock solu-
tions of chloroquine diphosphate were prepared in water
(Biosedra, France) and stock solutions of quinine hydro-
chloride, mefloquine, lumefantrine, artemether and
artesunate were prepared in ethanol. Further two-fold
serial dilutions were prepared in distilled water (Biosedra,
France). The final concentrations ranged from 0.05 to
51.2 nM for artesunate, 1 to 1024 nM for mefloquine, 5 to
5120 nM for chloroquine, 6.2 to 6400 nM for quinine,
0.1953 to 200 nM for lumefantrine and 0.097 to 100 nM
for artemether. Each concentration was used to coat two
wells of a Falcon 96-well, flat-bottom plate (ATGC,
France). Forty microliters of drug solutions prepared as
described above was added to each well and plates were
then dried at room temperature in a sterile cabinet. The
pre-dosed plates were finally kept frozen at -20°C until
use. Their suitability for in vitro testing was regularly mon-
itored using reference strains maintained in continuous
culture (at Institut Pasteur in Cambodia) and presenting
known responses to the various drugs tested.
In vitro assay
The in vitro drug sensitivity of the Cambodian isolates
was assessed by use of a classical isotopic 48 h test [11].
Briefly, fresh blood samples were washed three times with
RPMI 1640 medium (GibcoTM, Invitrogen Corporation,
France) by centrifugation (800 g, 10 min). The parasites
were then tested directly without culture adaptation. The
infected erythrocytes (1.5% haematocrit, 0.1–1% parasi-
taemia) were suspended in complete RPMI medium sup-
plemented with 10% AB+ human serum that was heat
inactivated for 30 min at 56°C (Biomedia, France) and
buffered with 25 mM/l Hepes and 25 mM/l NaHCO3. The
mixture was distributed (200 μl per well) into the 96-well
test plates that had been pre-coated with anti-malarial
agents. Each plate included two drug-free control wells
and one control well without parasites. The culture plates
were incubated for 48 h at 37°C in a 5%CO2 atmosphere.
[3H]-hypoxanthine (0.5 μCi/well; Amersham Biosciences,
France) was used to assess parasite growth. Each isolate
was tested once in duplicate in the microplates with serial
dilutions of drugs. Drug response was quantified by mon-
itoring [3H]hypoxanthine uptake in a Wallac MicroBeta
Trilux counter (Perkin-Elmer, France). At the end of the
incubation period, the plates were frozen at -20°C and
thawed to lyse the cells. After collection on glassfiber filter
paper using a cell harvester, the amount of [3H]-hypoxan-
thine incorporated into the parasites nucleoprotein was
determined. The results of in vitro assay are expressed as
the 50% inhibitory concentration (IC50), defined as the
concentration at which 50% of the incorporation of [3H]-
hypoxanthine was inhibited, as compared with in the
drug-free control wells. Parasite growth was measured by
using a log probit approximation to determine the
IC50values.
DNA extraction
Parasite DNA was extracted from frozen blood aliquots
(200 μl) using High Pure PCR template preparation kit
(Roche®) following the manufacturers protocol. Blood
stored on filter paper was extracted using QIAamp DNA
Mini Kit (Qiagen) [12].
Genetic polymorphism
Paired samples taken at enrollment and at recurrence of
parasitaemia were used to distinguish between recrudes-
cence and re-infection. The number of variants in three
polymorphic genes (msp1, msp2 and glurp) was deter-
mined as described previously [13,14]. If the sample
taken at recurrence contained either a subset of, or the
same variants as the enrollment specimen, the infection
was classified as recrudescence. If not, the infection was
classified as a re-infection. The amplification of a single
fragment at these three loci indicated that the parasite
population was mono-infected (single genotype). Detec-Malaria Journal 2009, 8:11 http://www.malariajournal.com/content/8/1/11
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tion of two or more PCR bands, at one or more loci, indi-
cated that the isolate contained multiple infections.
PCR amplification and direct sequencing were used to
determine the single nucleotide polymorphism (SNP) at
four pfmdr1 sites (positions 86, 184, 1042, and 1246) at
enrollment date. The primer sequences used for the anal-
ysis of the N86Y and Y184F SNPs were: first amplification,
5'-TTA AAT GTT TAC CTG CAC AAC ATA GAA AAT T-3'
(forward) and 5'-CTC CAC AAT AAC TTG CAA CAG TTC
TTA-3' (reverse); nested amplification, 5'-TGT ATG TGC
TGT ATT ATC AG GA-3' (forward) and 5'-CTC TTC TAT
AAT GGA CAT GGT A-3' (reverse). The primer sequences
used for the analysis of the N1042D and D1246Y SNPs
were: first amplification, 5'-AAT TTG ATA GAA AAA GCT
ATT GAT TAT AA-3' (forward) and 5'-TAT TTG GTA ATG
ATT CGA TAA ATT CAT C-3' (reverse); nested amplifica-
tion, 5'-GAA TTA TTG TAA ATG CAG CTT TA-3' (forward)
and 5'-GCA GCA AAC TTA CTA ACA CG-3' (reverse). PCR
products were sent to Genopole, Institut Pasteur Paris
(IPP) for sequencing. Sequencing reactions were per-
formed from both ends using ABI Prism BigDye Termina-
tor Cycle Sequencing-Ready Reaction kits, and were run
on a 3700 Genetic Analyzer (Applied Biosystems) as
described previously [15]. Sequencing results were assem-
bled, individually visually examined, and aligned using
ABI Prism® SeqScape® software version 2.5 (Applied Bio-
systems).
Real time PCR
Real time PCR was performed with an ABI PRISM 7000
sequence detection system (Applied Biosystems, Foster
City, CA). Pfmdr1 copy number was assessed for all enroll-
ment samples using a previous assay [5]. This assay con-
sisted of combining both the primers and a FAM-TAMRA
probe specific to a conserved region of pfmdr1, and the
primers and a VIC-TAMRA probe specific for β-tubulin, all
in one reaction. The primers were synthesized by Sigma-
Proligo (Proligo Singapore Pty Ltd) and the probes were
synthesized by Applied Biosystems UK. All samples were
run in duplicate in 25 μl reactions. The reagents used for
each unknown sample or standard were 1X Abgene QPCR
ROX Master mix (2X, Abgene), 300 nM of each forward
and reverse pfmdr1 primer, 150 nM of pfmdr1 probe, 100
nM of each forward and reverse β-tubulin primer and β-
tubulin  probe, 2 μl of template DNA and sterile water
(Biosedra, Fresenius Kabi, France). DNA from strains 3D7
and Dd2 were included on each plate. The 3D7 DNA and
Dd2 DNA were acquired from MR4 [16]. The reaction
mixtures were prepared at 4°C in a 96-well optical reac-
tion plate (Applied Biosystems) covered with optical
adhesive covers (Applied Biosystems). The thermal
cycling conditions were 50°C for 2 min, 95°C for 15 min
and then 50 cycles of 95°C for 15 s and 60°C for 1 min.
The threshold was placed to optimize the threshold cycle
(CT) value for the first standardization reaction, and all
subsequent CT values were obtained by using the same
threshold value. Pfmdr1  copy number was calculated
according to the following formula: copy number = (Eβtu-
bulin)CT(βtubulin)/(Epfmdr1)CT(pfmdr1). The Efficiency (E) of the β-
tubulin was assumed to be 2. Each plate included 1 well of
3D7 DNA (which has a copy number of 1) and 1 well Dd2
(which has 4 copies). The efficiency of the pfmdr1 was
back calculated using CT's for 3D7 and Dd2 in the previ-
ous formula [17,18].
Statistical analysis
All statistical analyses were performed using STATA
(StataSE 8, Stata Corporation, College Station, Texas). The
in vitro activity of anti-malarials is expressed as the geo-
metric means of the IC50s for all isolates. Drug concentra-
tions were transformed into logarithms. Linear regression
analysis was used to assess the relationship between the
prevalence of parasite and pfmdr1 copy number. The asso-
ciation between pfmdr1 copy number and treatment fail-
ure or IC50  of each anti-malarial drug was tested by
Wilcoxon rank-sum (Mann-Whitney) test. The relation-
ship between molecular changes in pfmdr1 and treatment
failure was estimated using survival analysis. Patients who
had been lost to follow-up or who presented again with
re-infection were included but censored at their last visit
or when they were diagnosed with a re-infection. All vari-
ables were assessed for the proportional hazard assump-
tion. The main outcome was time to recrudescence.
Previously identified risks for treatment failure with
mefloquine and artesunate, and with lumefantrine and
artemether, were included in Cox's regression analysis
when assessing the association of pfmdr1 polymorphisms
and treatment response. For all statistical tests, the signif-
icance level was set at p = 0.05.
Ethical approval
This study was approved by the National Ethics Commit-
tee for Health Research, Ministry of Health, Cambodia,
and the Technical Review Group of WHO/WPRO.
Results
Genetic diversity
At enrollment, 187 of 227 (82%) patient blood samples
contained only one parasite population, with a single gen-
otype at the msp1, msp2 and glurp loci, whereas 40 (18%)
had multiple infections containing two (38/227 or 17%)
or three (2/227 or 1%) distinct genotypes. The number of
parasite populations in three isolates remained undeter-
mined due to the poor quality of typing with three mark-
ers. The mean number of clones per isolate was 1.18 and
standard deviation was 0.41.Malaria Journal 2009, 8:11 http://www.malariajournal.com/content/8/1/11
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Pfmdr1 polymorphism
One hundred and sixty two patient blood samples were
randomly selected for pfmdr1 sequencing at position of
pfmdr1-86, 184, 1042 and 1246. One hundred and fifty
six patient blood samples (96.3%) gave interpretable
results (Figure 1). Out of these, 18 were unsuccessfully
sequenced at pfmdr1-86, 17 were unsuccessful at pfmdr1-
184, 1 was unsuccessful at pfmdr1-1042 and 1 was unsuc-
cessful at pfmdr1-1246. No Pfmdr1-86-Tyr and pfmdr1-
1246-Tyr mutants were observed. The results showed 125
(91%)  pfmdr1-184-Phe mutant isolates and 11 (8%)
pfmdr1-1042-Asp mutant isolates. No Pfmdr1-86-Tyr and
pfmdr1-1246-Tyr mutants were observed.
Pfmdr1 copy number
The pfmdr1 copy number was determined for 115 isolates
in the AM group and for 109 isolates in the AL group, all
collected at the day of enrollment (Figure 1). An overall
mean copy number of 1.55 with a range from 0.56 to
4.91. Control DNA gave reproducible results as Dd2 had
a mean copy number of 4.05 with a standard deviation of
0.47, and 3D7 control group had a mean copy number of
1.16 with a standard deviation of 0.14.
When rounded to the nearest integer, 182 (81%) isolates
had a pfmdr1 copy number of one, 28 (12%) had two cop-
ies, 8 (4%) had three copies, and 6 (3%) had four copies.
Overall, copy number was not related to baseline parasi-
taemia, age or gender (results not shown). No pfmdr1 pol-
ymorphisms were found to be associated with increased
copy number. Genetic polymorphisms at the msp1, msp2
and glurp loci showed no indication of clonal population
structure in high copy number isolates.
In vitro drug sensitivity
In vitro sensitivities to artesunate, mefloquine, quinine
and chloroquine were determined for 226 isolates. Micro-
scopic examination showed that the parasite loads were
between 0.02 and 14.4%, with a mean parasitaemia of
1.27%, CI 95% (1.02 – 1.52). Consistent with previous
findings indicating that parasitaemia is critical for ade-
quate in vitro testing, interpretable data for at least one of
the drugs tested were obtained only for about half of the
isolates (43.8%) (Figure 1). Other samples with low para-
site counts (< 0.2%, n = 60) resulted in poor quality data
and were not included in the study. In vitro sensitivity for
artemether and lumefantrine were only tested on the AL
group with 40 and 50 interpretable results, respectively
(Figure 1). The geometric mean IC50 values for meflo-
Number of specimens analyzed for in vitro drug sensitivity, pfmdr1 polymorphism and pfmdr1 copy number according to the  treatment group Figure 1
Number of specimens analyzed for in vitro drug sensitivity, pfmdr1 polymorphism and pfmdr1 copy number 
according to the treatment group. N: Number. #Mey Bouth Denis et al, December 2006, Tropical Medicine and Interna-
tional Health [8]. *Mey Bouth Denis et al, September 2006, Tropical Medicine and International Health [9].Malaria Journal 2009, 8:11 http://www.malariajournal.com/content/8/1/11
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quine, artesunate, quinine, chloroquine, lumefantrine
and for artemether were 20.2 nM/l (n = 92, CI95% 16.1 –
25.3 nM, range 2.3 – 132.9), 1.3 nM/l (n = 99, CI95% 1.1
– 1.5 nM, range 0.3 – 11.1), 131.6 nM/l (n = 90, CI95%
115 – 150.7 nM, range 19.94 – 615.9), 196.1 nM/l (n =
90, CI95% 176.1 – 218.3 nM, range 54.1 – 663.3), 19.27
nM/l (n = 50, CI95% 15.8 – 23.4 nM, range 3.6 – 79.2)
and 1.00 nM/l (n = 40, CI95% 0.6 – 1.6 nM, range 0.2 –
42.2), respectively.
The relationships between increased pfmdr1 copy number
and in vitro drugs susceptibilities were then analysed.
Pfmdr1 copy number has been regouped into low (< 2
copies) and high (≥ 2 copies). Parasites with increased
pfmdr1 copy number demonstrated significantly reduced
susceptibilities to mefloquine and lumefantrine (p < 0.01,
Table 1). These strains also showed reduced susceptibili-
ties to endoperoxides and increased susceptibility to chlo-
roquine, but these differences did not reach significant
levels. No association was found with in vitro susceptibil-
ity to quinine (Table 1). Similarly, no association was
found between pfmdr1 genotype and in vitro results for
any tested drugs.
In vivo study
In vivo outcome was reported previously by Denis MB et
al, 2006 [8,9] and is summarized in table 2. As deter-
mined by msp1 , msp2 and glurp genotyping, 10 in the AM
group and 23 in the AL group were classified as recrudes-
cence. All failures were late treatment failures (LTF = LCF
+ LPF). In summary, there were 96 (81%) ACPR and 23
(19%) LTF in AL group and 123 (92.5%) ACPR and 10
(7.5%) LTF in the AM group (Figure 1).
Pfmdr1 copy number was lower in the ACPR group com-
pared to the LTF group (n = 112, p < 0.001) for AM but not
for AL treatment (n = 96, p = 0.257) (Figure 2). The pro-
portional hazards assumption was violated when pfmdr1
copy number was classified as a single copy versus multi-
ple copies. Therefore, to allow statistical analysis of copy
number data, two groups were build: low (< 3 copies) and
high (≥ 3 copies). A pfmdr1 copy number that is ≥ 2.5 is
rounded up to 3. This way of coding copy number met the
proportional hazards assumption.
In the AM group (N = 115), crude hazard ratio for
increased copy number (≥ 3 copies compared to < 3 cop-
ies) was 7.80 [95%CI: 2.09–29.10], p = 0.002. After con-
trolling for baseline parasitaemia and gender in a Cox's
regression model, the hazard ratio was 12.28 [95%CI:
3.19–47.30], p < 0.001. There was no association between
increased copy number and treatment failure in the AL
group [HR = 1.03 [95%CI: 0.24–4.46], p = 0.962] (Figure
3).
Discussion
The involvement of pfmdr1 in anti-malarial resistance has
been suspected since the 1990's but practical use of this
information had to wait for methodological improve-
ments and the availability of high quality quantitative
PCR in endemic areas. This is now possible in a basic
molecular laboratory. In this study, increased pfmdr1 copy
number was associated with AM recrudescence. The asso-
ciation between pfmdr1 copy number and treatment fail-
ure to mefloquine-based regimens has been consistently
found in both Cambodia and Thailand [5-7]. In addition,
mefloquine monotherapy and combination therapy has
previously been shown to select for increased pfmdr1 copy
number within a host [5,19]. Increased pfmdr1  copy
number was also associated with decreased in vitro sus-
ceptibility to mefloquine, lumefantrine and, to a lesser
degree artesunate, which is consistent with previous stud-
ies [20-22]. It is not clear whether the association between
pfmdr1 copy number and AM failure is mediated by resist-
ance to mefloquine alone or in conjunction with
decreased sensitivity to artesunate. Further studies of this
question are required.
In vitro drug sensitivity was successfully assayed in only
44% of the blood specimens. This high failure rate is likely
to result from low parasite counts. However, some other
factors such as poor transport condition from field sites to
Table 1: Correlation between IC50 and pfmdr1 copy number outcome.
Single pfmdr1 copy number Increased pfmdr1 copy number** p*
Number Mean IC50 (range) nM/l Number Mean IC50 (range) nM/l
Mefloquine 73 27.9 (2.3 – 132.4) 17 50.3 (9.6 – 132.9) 0.007
Artesunate 80 1.6 (0.3 – 11.1) 17 2.1 (0.6 – 5.6) 0.054
Lumefantrine 45 21.4 (3.6 – 63.5) 5 44.1 (25.9 – 79.2) 0.006
Artemether 33 2.2 (0.2 – 17) 7 7.6 (0.2 – 42.2) 0.143
Quinine 73 158.2 (26.1 – 615.9) 16 172.3 (19.9 – 612.2) 0.677
Chloroquine 73 235.4 (54.1 – 663.3) 16 175.6 (71.4 – 331.9) 0.085
*Significance level (p) was 0.05. The analysis was tested by Wilcoxon rank-sum (Mann-Whitney) test.
**The cutoff of pfmdr1 multicopy was 2 copies.Malaria Journal 2009, 8:11 http://www.malariajournal.com/content/8/1/11
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laboratory, or prolonged storage of infected blood at 4°C
or presence of drug trace in the sample may have similarly
interfere with the performance of the test [4]. These factors
raise the possibility that the failure of certain strains to
grow in vitro may not have been determined randomly,
but may have been associated, for example, with
decreased fitness, perhaps linked to decreased drug sensi-
tivity. Therefore, measured in vitro IC50s may not be rep-
resentative of the full set of samples studied for clinical
outcomes and molecular features.
Interestingly,  pfmdr1  copy number had apparently no
impact on clinical AL failure even though it was associated
with decreased in vitro susceptibility to both artemether
and lumefantrine [19,22]. This could be related to the
overall low pfmdr1-associated increase of IC50's for these
drugs (Table 1). Another possibility is that the AL clinical
failures in this study might result from poor lumefantrine
absorption. Actually, oral bioavailability of lumefantrine
has been shown to be considerably reduced during the
acute phase of malaria and also to vary from one individ-
ual to another. It is therefore possible that the fraction
absorbed by patients did not reach optimal curative levels,
leaving unaffected some residual parasites. However, this
possibility is probably not major issue in this study as an
association between increased pfmdr1 copy number and
decreasing in vitro susceptibility to lumefantrine was at
the same time observed, suggesting that AL failure could
indeed result from decreased susceptibility to lumefan-
trine. Because of the exponential growth of Coartem® use
in the past 5 years, high selection pressure could also be
acting in Africa. The monitoring of drug resistance to
Table 2: In vivo outcome measures
Study Number of patients Treatment outcome (n. %)
Included Drop out* Analysed ACPR LTF LPF LCF
AL2002† 55 10(4) 45 32(71.1) 13(28.9) 2(4.4) 11(24.5)
AL2003† 80 6(3) 74 64(86.5) 10(13.5) 6(8.1) 4(5.4)
AM2003‡ 55 3(0) 52 48(92.3) 4(7.7) 3(5.7) 1(2)
AM2004‡ 85 4(1) 81 75(92.6) 6(7.4) 0(0) 6(7.4)
ACPR. Adequate Clinical and Parasitological Response; LTF. Late Treatment Failure;
LCF. Late Clinical Failure; LPF. Late Parasitological Failure; LTF = LCF + LPF.
*Number between parenthesis indicates the number Plasmodium vivax infections
†Artemether 20 mg/kg and lumefantrine 120 mg/kg
‡Artesunate 12 mg/kg and mefloquine 25 mg/kg
Comparison of pfmdr1 copy number and clinical failure outcome Figure 2
Comparison of pfmdr1 copy number and clinical failure outcome. Artesunate-mefloquine: ACPR (N = 103, copy 
number ≥ 2 = 20); LTF (N = 9, copy number ≥ 2 = 7); * p < 0.001. Artemether-lumefantrine: ACPR (N = 76, copy number ≥ 2 
= 8); LTF (N = 20, copy number ≥ 2 = 4), p = 0.257 (the analysis was tested by Wilcoxon rank-sum (Mann-Whitney) test). The 
black horizontal lines and number represent geometric mean pfmdr1 copy number.Malaria Journal 2009, 8:11 http://www.malariajournal.com/content/8/1/11
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lumefantrine is thus important for national anti-malarial
treatment policy particularly in African countries.
Conclusion
This study shows that pfmdr1 copy number is a molecular
marker of AM treatment failure in falciparum malaria on
the Cambodia-Thailand border. However, while it is asso-
ciated with increased IC50 for lumefantrine, pfmdr1 copy
number is not associated with AL treatment failure in the
area, suggesting involvement of other factors or molecular
mechanisms in AL treatment failures in Cambodia.
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